Skip to content

Efficacy and Mechanisms of Auricular Acupressure Combined with Bloodletting Therapy in Ischemic Stroke Patients: A Randomized Controlled Trial

Efficacy and Mechanisms of Auricular Acupressure Combined with Bloodletting Therapy in Ischemic Stroke Patients: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001009
Enrollment
Unknown
Registered
2025-05-19
Start date
2024-02-01
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ischemic stroke

Interventions

Auricular Acupressure Group (group B for short):Auricular Acupressure
Bloodletting Group (group A):Bloodletting Therapy
Auricular Acupressure Combined with Bloodletting Therapy Group (C group for short):Auricular Acupressure Combined with Bloodletting Therapy

Sponsors

Hunan University of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients must meet all of the following criteria to be eligible for enrollment: ?Diagnosis of ischemic stroke according to both Chinese and Western medical standards ?Diagnosis of stroke- ?Zhong Jingluo ?( ?middle meridian ?) - Wind-Fire Disturbance Syndrome; ?Second episode of stroke with clear consciousness limb dysfunction and disease course = 2 weeks; ?Upper limb function classified as Brunnstrom stage II-IV; ?Age between 40 and 80 years (inclusive) with no restriction on gender; ?Voluntary participation and provision of informed consent.

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria should be excluded: ?Patients with severe mental disorders or loss of consciousness; ?Patients with clinically unstable conditions severe intellectual disabilities or inability to comply with or understand the trial procedures; ?Patients with motor dysfunction caused by cranial trauma lower motor neuron injury intracranial space-occupying lesions or spinal cord injuries; ?Patients with a history of epileptic seizures or severe organic diseases of the heart liver or kidneys; ?Patients intolerant to the treatment methods.

Design outcomes

Primary

MeasureTime frame
the Barthelindex of ADL;Fugl-Meyer assessment;

Secondary

MeasureTime frame
KCTD10;VEGF;HIF-1a;

Countries

China

Contacts

Public ContactCai zhenjin

Hunan University of Chinese Medicine

zhenjincai@outlook.com13348765659

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026